Image Alt
 • Beauty  • Could This Jab Really Solve Our Cellulite Woes

Could This Jab Really Solve Our Cellulite Woes

You are not alone, 85-90% of women suffer from some sort of cellulite on their bodies. Cellulite affects women of different body shapes and sizes and is not correlated with the percentage of body fat of a woman.

Men interestingly are much less likely to have cellulite, simply because their bodies are created differently. Just to recap before diving into this treatment that has actually been FDA approved for cellulite appearing on the buttocks specifically. 

Cellulite is the dimpling of the skin around pockets of fat, skin appears non-uniform and bumpy. Cellulite is caused by bands of collagen (septae) that connect the skin to the muscle. As fat is deposited between the skin and the muscle, these bands tighten causing the pockets of fat to appear as round circles or dimples on the surface of the skin.

To date, the agreed-on technique for reducing cellulite is to cut or severe these bands that hold the skin to the muscle, thus releasing the tightness and reducing the appearance of the fat pockets. In the past this cutting of the collagen bands (septae) has been done using the heat from lasers, the Cellfina treatment takes it a little further by cutting the bands using an actual blade. There is also the traditional technique of severing the bands manually using a cannula under the skin. All these treatments have had temporary results, that last up to 3 years maximum.

QWO (collagenase clostridium histolyticum-aaes) is a treatment that is directly injected into each of the dimples releasing the septae chemically, and this is the main difference and advantage of QWO. Once injected, the QWO is thought to target collagen types 1 and 3, releasing the septae, which naturally releases the pockets of fat between the skin and muscle. This process is much less invasive and the downtime after the procedure is much shorter. 

The QWO injectables are administered in 12 injection treatments, 21 days apart, depending on the amount and severity of the case of course. This treatment was introduced to US clinics in Spring 2021, watch out for its ultimate release in the MENA region soon!